Skip to main content
ARTV
NASDAQ Life Sciences

RA Capital, a major investor and director, buys another $7.65M in Artiva Biotherapeutics stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$7.6
Mkt Cap
$197.733M
52W Low
$1.47
52W High
$14.53
52W Position info
417% above low
Off High info
48% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

ARTV has more than doubled off its 52-week low of $1.47 on elevated volume (2.4× avg).

Summary

Major institutional investor RA Capital, with board representation, made an additional $7.65 million open market purchase of Artiva Biotherapeutics stock, signaling continued strong conviction.


Key Events · Ownership and Investor Activity · ARTV

  • Significant Insider Purchase

    RA Capital Healthcare Fund LP, a 10% owner and director, purchased $7,650,148 worth of common stock in open market transactions between June 9 and June 11, 2026.

  • Continued Institutional Confidence

    This purchase represents a substantial increase in holdings by a major institutional investor, following previous large buys by RA Capital and another 10% owner (GC Corp.) in May.

  • Transaction Details

    The shares were acquired in three transactions at weighted average prices ranging from $6.91 to $7.91.


Analysis · ARTV · Life Sciences

RA Capital Healthcare Fund LP, a significant institutional investor with board representation, has continued to increase its stake in Artiva Biotherapeutics with a substantial open market purchase of $7.65 million. This follows a previous $100 million purchase by RA Capital in May and another $16.5 million purchase by GC Corp. in late May, indicating strong and sustained institutional confidence in the company.

How filings like this one have moved

In the 30 days to Sep 18, 2026, 40.1% of the 367 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARTV was trading at $7.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $197.7M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARTV - Latest Insights

ARTV
Aug 06, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.58
Real-time Price: $8.64 info
Change: -$2.94 (-25%) info
Market Cap: $422.411M info
ARTV
Jul 23, 2026, 9:23 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $10.13
Real-time Price: $8.64 info
Change: -$1.49 (-15%) info
Market Cap: $422.411M info
ARTV
Jul 23, 2026, 9:22 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $10.13
Real-time Price: $8.64 info
Change: -$1.49 (-15%) info
Market Cap: $422.411M info
ARTV
Jul 20, 2026, 6:08 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $9.12
Real-time Price: $8.64 info
Change: -$0.4767 (-5%) info
Market Cap: $422.411M info
ARTV
Jun 16, 2026, 6:08 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $8.90
Real-time Price: $8.64 info
Change: -$0.260 (-3%) info
Market Cap: $422.411M info